Moderna shares continue to fall even as its 3 vaccines enter final stage trials

Moderna Inc. saw its stock continue its downward trajectory on Wednesday morning, slipping by 1.2 percent to $106.21, following a decline of over 3 percent on Tuesday. The biotech company’s shares have endured a 28% drop over the past year. Moderna’s 3 vaccines advance Despite the stock decline, Moderna announced positive clinical trial results for […]